Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Hidradenitis Suppurativa
NCT03713619Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (4 arms), sponsored by Novartis. Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR50) at 16 weeks. Started Jan 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03713619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713619.